Disease · MONDO_0005494

triple-negative breast carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. triple-negative breast carcinoma. Diseases, record MONDO_0005494. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005494

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: triple-negative breast carcinoma; Open Targets
Open Targets ID: MONDO_0005494; Open Targets
Other names: TNBC, triple-negative breast cancer, triple-receptor negative breast cancer; Open Targets
Disease Ontology: DOID:0060081; Disease Ontology
MeSH: D064726; MeSH
NCI Thesaurus: C71732; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 320 drugs, from FDA; Open Targets

Drugs320

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SACITUZUMAB GOVITECAN	CHEMBL3545262	Antibody drug conjugate	Approval	FDA	30	29	29	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	157	157	134	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	100	100	100	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	90	90	90	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	62	62	62	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	37	37	37	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	36	36	36	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	33	33	30	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	28	28	28	Drugs and targets

1 to 10 of 320

See all 320 drugs

Targets324

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	15	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	13	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
TUBA1A	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 324

See all 324 targets

Trials531

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors	Phase 1/2	1,163	2020-03-24	Advanced or Metastatic Solid Tumors	COBIMETINIB, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02425891	A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)	Phase 3	902	2021-05-17	Triple Negative Breast Cancer	ATEZOLIZUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02819518	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)	Phase 3	882	2022-07-05	Triple Negative Breast Cancer (TNBC)	CARBOPLATIN, GEMCITABINE, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03125902	A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)	Phase 3	653	2021-01-07	Triple-Negative Breast Cancer	ATEZOLIZUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03371017	A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer	Phase 3	595	2025-11-12	Triple Negative Breast Neoplasms	ATEZOLIZUMAB, CAPECITABINE, CARBOPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00600340	2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab	Phase 3	564	2019-12-30	Metastatic Breast Cancer	BEVACIZUMAB, CAPECITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01631552	Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer	Phase 1/2	515	2021-04-06	Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer	SACITUZUMAB GOVITECAN	Its record names the disease	ClinicalTrials.gov
NCT02460224	Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.	Phase 1/2	490	2022-02-10	Advanced Solid Tumors	IERAMILIMAB, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04191135	Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)	Phase 2	462	2024-02-14	Triple Negative Breast Neoplasms	CARBOPLATIN, GEMCITABINE, OLAPARIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04770272	Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy	Phase 2	442	2026-01-12	Triple-negative Breast Cancer	ATEZOLIZUMAB, CARBOPLATIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 531

See all 531 trials

Comparisons in its trials86

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo (q2w) + Nab-Paclitaxel vs Atezolizumab (q2w) + Nab-Paclitaxel: deaths from any cause	333 of 451	314 of 451	902	NCT02425891	Trial comparisons
Placebo (q2w) + Nab-Paclitaxel vs Atezolizumab (q2w) + Nab-Paclitaxel: serious adverse events	80 of 430	110 of 460	890	NCT02425891	Trial comparisons
Atezolizumab + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause	229 of 431	119 of 220	651	NCT03125902	Trial comparisons
Atezolizumab + Paclitaxel vs Placebo + Paclitaxel: serious adverse events	112 of 431	40 of 220	651	NCT03125902	Trial comparisons
Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: Number of Participants With Adverse Events (AEs)	283 of 294	281 of 293	587	NCT03371017	Trial comparisons
Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: deaths from any cause	233 of 294	226 of 293	587	NCT03371017	Trial comparisons
Placebo + Chemotherapy vs Atezolizumab + Chemotherapy: serious adverse events	57 of 294	69 of 293	587	NCT03371017	Trial comparisons
Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: deaths from any cause	196 of 284	209 of 277	561	NCT00600340	Trial comparisons
Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: serious adverse events	65 of 284	68 of 277	561	NCT00600340	Trial comparisons
Arm A vs Arm B: Disease Free Survival (DFS)	15 of 180	10 of 179	359	NCT04770272	Trial comparisons

1 to 10 of 86

See all 86 comparisons in its trials

Papers from its trials323

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41405563	RESULT	1	PubMed
40762544	RESULT	1	PubMed
40499147	RESULT	1	PubMed
39302614	RESULT	2	PubMed
38642937	RESULT	1	PubMed
38422473	RESULT	1	PubMed
37593227	RESULT	1	PubMed
36482103	RESULT	1	PubMed
35324390	RESULT	1	PubMed
33882206	RESULT	1	PubMed

1 to 10 of 323

See all 323 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005494

GET https://conductscience.org/api/diseases/v1/MONDO_0005494/drugs?page=2

API reference For AI assistants